Literature DB >> 11323525

The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury.

J A Cheney1, J D Weisser, F M Bareyre, H L Laurer, K E Saatman, R Raghupathi, V Gribkoff, J E Starrett , T K McIntosh.   

Abstract

Large-conductance, calcium-activated potassium (maxi-K) channels regulate neurotransmitter release and neuronal excitability, and openers of these channels have been shown to be neuroprotective in models of cerebral ischemia. The authors evaluated the effects of postinjury systemic administration of the maxi-K channel opener, BMS-204352, on behavioral and histologic outcome after lateral fluid percussion (FP) traumatic brain injury (TBI) in the rat. Anesthetized Sprague-Dawley rats (n = 142) were subjected to moderate FP brain injury (n = 88) or surgery without injury (n = 54) and were randomized to receive a bolus of 0.1 mg/kg BMS-204352 (n = 26, injured; n = 18, sham), 0.03 mg/kg BMS-204352 (n = 25, injured; n = 18, sham), or 2% dimethyl sulfoxide (DMSO) in polyethylene glycol (vehicle, n = 27, injured; n = 18, sham) at 10 minutes postinjury. One group of rats was tested for memory retention (Morris water maze) at 42 hours postinjury, then killed for evaluation of regional cerebral edema. A second group of injured/sham rats was assessed for neurologic motor function from 48 hours to 2 weeks postinjury and cortical lesion area. Administration of 0.1 mg/kg BMS-204352 improved neurologic motor function at 1 and 2 weeks postinjury (P < 0.05) and reduced the extent of cerebral edema in the ipsilateral hippocampus, thalamus, and adjacent cortex (P < 0.05). Administration of 0.03 mg/kg BMS-204352 significantly reduced cerebral edema in the ipsilateral thalamus (P < 0.05). No effects on cognitive function or cortical tissue loss were observed with either dose. These results suggest that the novel maxi-K channel opener BMS-204352 may be selectively beneficial in the treatment of experimental TBI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323525     DOI: 10.1097/00004647-200104000-00008

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  16 in total

1.  Characterisation of a novel class of polyamine-based neuroprotective compounds.

Authors:  Ashley K Pringle; Barclay Morrison; Mark Bradley; Fausto Iannotti; Lars E Sundstrom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-06       Impact factor: 3.000

2.  Cognitive evaluation of traumatically brain-injured rats using serial testing in the Morris water maze.

Authors:  Hilaire J Thompson; David G LeBold; Niklas Marklund; Diego M Morales; Andrew P Hagner; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2006       Impact factor: 2.406

Review 3.  Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.

Authors:  Michele Ferrante; Kim T Blackwell; Michele Migliore; Giorgio A Ascoli
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 4.  Mitochondrial mechanisms in cerebral vascular control: shared signaling pathways with preconditioning.

Authors:  David W Busija; Prasad V Katakam
Journal:  J Vasc Res       Date:  2014-05-22       Impact factor: 1.934

5.  Down-regulation of BK channel expression in the pilocarpine model of temporal lobe epilepsy.

Authors:  Luis F Pacheco Otalora; Eder F Hernandez; Massoud F Arshadmansab; Sebastian Francisco; Michael Willis; Boris Ermolinsky; Masoud Zarei; Hans-Guenther Knaus; Emilio R Garrido-Sanabria
Journal:  Brain Res       Date:  2008-01-18       Impact factor: 3.252

Review 6.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.

Authors:  Valentin K Gribkoff; Leonard K Kaczmarek
Journal:  Neuropharmacology       Date:  2016-03-12       Impact factor: 5.250

Review 7.  The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success.

Authors:  Ryan C Turner; Sean C Dodson; Charles L Rosen; Jason D Huber
Journal:  J Neurosurg       Date:  2013-01-18       Impact factor: 5.115

8.  The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.

Authors:  Carrie A Keck; Hilaire J Thompson; Asla Pitkänen; David G LeBold; Diego M Morales; Jamie B Plevy; Rishi Puri; Boyu Zhao; Marc Dichter; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

Review 9.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 10.  Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning.

Authors:  David W Busija; Tamas Gaspar; Ferenc Domoki; Prasad V Katakam; Ferenc Bari
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.